case_images: PMC6806533_01
case_images: Fundus photographs from Cases 1, 2, and 3, before and after intravitreal injection of rAAV2-ND4. (Left) Fundus photographs of the three patients before surgery. (Right) Fundus photographs of the three patients after surgery. No structural abnormalities of the retina were found in any of the patients.
case_images: CGT-19-134_F1.jpg
case_images: PMC6806533_01_CGT-19-134_F1.jpg
case_images: F1
case_images: The patient was followed up for the first and third month after injection, and his visual acuity improved to 20/33(0.2LogMAR) and 20/40 (0.3LogMAR) at third month after surgery (Fig. 1).
case_images: PMC6806533_02
case_images: Visual acuity (logMAR) before, 4 days, 1 month(Case 2) and 3 months(Case 1 and Case 3) after injection of rAAV2-ND4 in three patients.
case_images: CGT-19-134_F2.jpg
case_images: PMC6806533_03_CGT-19-134_F2.jpg
case_images: F2
case_images: The patient was followed up for the first and third month after injection, and his BCVA of her injected and uninjected reached to 20/666(1.5LogMAR) and 20/1000(1.7LogMAR) respectively at the third month after surgery (Fig. 2).
case_images: PMC6806533_03
case_images: Visual acuity (logMAR) before, 4 days, 1 month(Case 2) and 3 months(Case 1 and Case 3) after injection of rAAV2-ND4 in three patients.
case_images: CGT-19-134_F2.jpg
case_images: PMC6806533_03_CGT-19-134_F2.jpg
case_images: F2
case_images: The patient was followed up for the first and third month after injection, and his BCVA of her injected and uninjected reached to 20/666(1.5LogMAR) and 20/1000(1.7LogMAR) respectively at the third month after surgery (Fig. 2).